Logo

    glp-1 agonist

    Explore " glp-1 agonist" with insightful episodes like "Meds for Obesity and Weight Loss", "Semaglutide GLP-1 for weight loss now??", "Addressing ART Safety and Tolerability in Transgender Individuals", "Novo Nordisk’s Ozempic (Semaglutide) Shortage and Fake Eli Lilly Twitter Account Announces Free Insulin" and "Elon Musk Reveals he Used Novo's Wegovy for Weight Loss + FDA Approval of Nevro's AI Spinal Cord Stimulation System" from podcasts like ""Medication Talk", "Great Health Does Not Have to Be A Mission Impossible!", "CCO Infectious Disease Podcast", "Xtalks Life Science Podcast" and "Xtalks Life Science Podcast"" and more!

    Episodes (6)

    Meds for Obesity and Weight Loss

    Meds for Obesity and Weight Loss

    Special guest Jennifer N. Clements, PharmD, FCCP, FADCES, BCPS, CDCES, BCACP, BC-ADM,  Clinical Professor and Director of Pharmacy Education from the University of South Carolina College of Pharmacy joins us to talk about meds for obesity and weight loss.

    Listen in as they discuss management of overweight and obesity, including the role of newer injectable medications, oral options, and lifestyle changes.

    You’ll also hear practical advice from panelists on TRC’s Editorial Advisory Board:

    • Stephen Carek, MD, CAQSM, DipABLM, Clinical Assistant Professor of Family Medicine, Prisma Health/USC-SOMG Family Medicine Residency Program at the USC School of Medicine Greenville
    • Andrea Darby Stewart, MD, Associate Director, Honor Health Family Medicine Residency Program and Clinical Professor of Family, Community & Occupational Medicine at the University of Arizona College of Medicine - Phoenix
    • Craig D. Williams, PharmD, FNLA, BCPS, Clinical Professor of Pharmacy Practice at the Oregon Health and Science University

    For the purposes of disclosure, Dr. Clements reports relevant financial relationships [GLP-1 agonists] with Eli Lilly, Novo Nordisk (speakers bureau).

    TRC Healthcare offers CE credit for this podcast. Log in to your Pharmacist’s Letter or Prescriber Insights account and look for the title of this podcast in the list of available CE courses.

    The clinical resources mentioned during the podcast are part of a subscription to Pharmacist’s Letter and Prescriber Insights


    If you’re not yet a Pharmacist’s Letter or Prescriber Insights subscriber, find out more about our product offerings at trchealthcare.com.

    Follow or subscribe, rate, and review this show in your favorite podcast app. You can also reach out to provide feedback or make suggestions by emailing us at
    ContactUs@trchealthcare.com.

    Addressing ART Safety and Tolerability in Transgender Individuals

    Addressing ART Safety and Tolerability in Transgender Individuals

    In this episode, Jill Blumenthal, MD, MAS, and Jennifer Cocohoba, PharmD, share how they manage possible antiretroviral (ARV)-associated toxicities in transgender individuals, including:

    • Strategies on how to approach different ARV-related toxicities
    • Other factors to consider when assessing possible ARV-related toxicities (eg, weight gain, cardiovascular disease), such as gender-affirming care and nonmedication risk factors (eg, smoking, life stressors)
    • Clinically relevant drug–drug interactions related to HIV and gender-affirming care
    • Methods to reduce barriers to ART adherence

    Faculty: 

    Jill Blumenthal, MD, MAS
    Associate Professor of Medicine
    Infectious Diseases and Global Public Health
    University of California, San Diego
    San Diego, California

    Jennifer Cocohoba, PharmD
    Professor
    Department of Clinical Pharmacy
    University of California, San Francisco
    Pharmacist
    Women’s HIV Program
    University of California San Francisco Medical Center
    San Francisco, California

    Link to full program:
    https://bit.ly/3PM3nYe

    Follow along with the slides at:
    https://bit.ly/3NpAYI1

    Novo Nordisk’s Ozempic (Semaglutide) Shortage and Fake Eli Lilly Twitter Account Announces Free Insulin

    Novo Nordisk’s Ozempic (Semaglutide) Shortage and Fake Eli Lilly Twitter Account Announces Free Insulin

    In this episode, Ayesha discussed Novo Nordisk’s Ozempic (semaglutide) shortage, largely attributed to off-label prescribing for weight loss and viral TikTok videos. The GLP-1 agonist is indicated as a type 2 diabetes treatment but has weight loss as a side effect. The shortage could give competitor Eli Lilly’s new dual GIP/GLP-1 agonist Mounjaro added market advantage, but can the company meet the unprecedented demand?

    Ayesha also talked about Eli Lilly falling victim to a fake Twitter account that tweeted the company was offering free insulin. The fraudulent account has a blue check, which users can purchase through a $8 per month subscription for the revamped Twitter Blue program introduced by Elon Musk. Lilly clarified the fake message, but the tweet has re-ignited debate about the cost of insulin in the US.

    Read the full articles here:

    Novo Nordisk’s Ozempic Shortage Spurs Demand for Eli Lilly’s Diabetes Injection Mounjaro

    Fraudulent Eli Lilly Twitter Account Announces Free Insulin

    For more life science and medical device content, visit the Xtalks Vitals homepage.

    Follow Us on Social Media

    Twitter: @Xtalks
    Instagram: @Xtalks
    Facebook: https://www.facebook.com/Xtalks.Webinars/
    LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
    YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    Elon Musk Reveals he Used Novo's Wegovy for Weight Loss + FDA Approval of Nevro's AI Spinal Cord Stimulation System

    Elon Musk Reveals he Used Novo's Wegovy for Weight Loss + FDA Approval of Nevro's AI Spinal Cord Stimulation System

    In this episode, Ayesha discussed Elon Musk’s recent revelation that in addition to fasting, he also used Novo Nordisk’s weight loss drug Wegovy to help him get “lean and fit.” In response to a question on Twitter, Musk disclosed that both fasting and Wegovy were his secrets to his recent weight loss. Musk is not affiliated with Novo so his endorsement of the drug came as a surprise, and is also problematic according to some. Hear more about the story in this episode.

    The editorial team also learned about the FDA approval of Nevro Corp’s AI-based spinal cord stimulation (SCS) system for the treatment of chronic pain. Nevro says its Senza HFX iQ system is the first and only AI-based SCS system that personalizes care by “learning from patients.” The implantable device delivers neurostimulation via the company’s proprietary high frequency pulse technology that has been evaluated in more than 90,000 patients. 

    Read the full articles here:

    Elon Musk Reveals Weight Loss Injection Wegovy Helped Him Get Lean and Fit

    Nevro’s AI-Based Spinal Cord Stimulation Device for Chronic Pain Receives FDA Approval

    For more life science and medical device content, visit the Xtalks Vitals homepage.

    Follow Us on Social Media

    Twitter: @Xtalks
    Instagram: @Xtalks
    Facebook: https://www.facebook.com/Xtalks.Webinars/
    LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
    YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    First FDA-Approved Treatment for Chronic Yeast Infection + Eli Lilly Obesity Drug Shows Promise in Trials

    First FDA-Approved Treatment for Chronic Yeast Infection + Eli Lilly Obesity Drug Shows Promise in Trials

    In this episode, Ayesha discussed the FDA approval of Mycovia Pharmaceuticals’ Vivjoa (oteseconazole) as the first approved treatment for recurrent vulvovaginal candidiasis (RVVC) or chronic yeast infection. The drug is indicated for women who permanently lack reproductive potential or are postmenopausal. The editorial team discussed the significant unmet need for this condition and how although many women’s health issues are now given greater spotlight, there still need to be more conversations around them. The episode marked World Maternal Mental Health Day and was sponsored by Elligo Health Research.

    The editorial team also talked about the latest results of Eli Lilly’s investigational obesity drug tirzepatide, which demonstrated it could reduce body weight by an average of 20 percent in individuals without diabetes. Tirzepatide is a GLP-1 receptor agonist, a class of drugs designed to treat diabetes but at higher doses, can help with weight loss. Hear more about the drug and the obesity drug market, which is projected to grow to $5.42 billion in 2025.

    Read the full articles here: 

    Oteseconazole (Vivjoa) Becomes First FDA-Approved Drug for Recurrent Yeast Infection

    Tirzepatide Obesity Drug Shown to Reduce Body Weight by 20 Percent in Eli Lilly Trial

    For more life science and medical device content, visit the Xtalks Vitals homepage.

    Follow Us on Social Media

    Twitter: @Xtalks
    Instagram: @Xtalks
    Facebook: https://www.facebook.com/Xtalks.Webinars/
    LinkedIn: https://www.linkedin.com/company/xtalks-webconferences
    YouTube: https://www.youtube.com/c/XtalksWebinars/featured

    Logo

    © 2024 Podcastworld. All rights reserved

    Stay up to date

    For any inquiries, please email us at hello@podcastworld.io